EPCAM and carcinoma: Decades later, in 2009, the field achieved a major milestone with market approval of the first bispecific Ab catumaxomab (Removab) against epithelial cell adhesion molecule (EpCAM) and CD3 markers to target malignant ascites that arise from epithelial carcinoma (26, 27).